Donepezil Krka (Donepezil Hydrochloride)

Donepezil Krka is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease. It may be prescribed to improve cognitive function, memory, and daily living activities in patients diagnosed with this neurodegenerative condition.

• Improves short‑term memory and attention in Alzheimer’s patients
• Supports daily functional abilities such as dressing and eating
• May be used as part of a comprehensive dementia management plan
• Typically prescribed when other non‑pharmacologic interventions are insufficient
• Can be considered for patients with mild to moderate disease severity

Side effects of Donepezil Krka vary in frequency and severity. Patients should be aware of both common and less frequent serious reactions.

Common

• Nausea or upset stomach
• Diarrhea or loose stools
• Insomnia or vivid dreams
• Muscle cramps or weakness
• Loss of appetite
• Fatigue or dizziness

Serious

• Severe bradycardia or heart block
• Gastrointestinal bleeding
• Hepatotoxicity (liver injury)
• Seizures
• Allergic reactions such as rash or angioedema

Before starting Donepezil Krka, certain health considerations should be reviewed to ensure safe use.

• Assess cardiac history, especially bradyarrhythmias or recent myocardial infarction
• Evaluate liver function, as hepatic impairment may affect drug metabolism
• Monitor for gastrointestinal ulcer disease or bleeding risk
• Use caution in patients with a history of seizures
• Review concomitant use of other cholinergic agents
• Discuss pregnancy and lactation status with a healthcare professional

Donepezil Krka can interact with several medications, requiring careful management.

Avoid

• Strong anticholinergic drugs (e.g., atropine, scopolamine) that may counteract its effect
• Certain antiarrhythmics (e.g., quinidine, procainamide) that can exacerbate cardiac effects
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) which may increase donepezil levels

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) due to ulcer risk
• Anticoagulants or antiplatelet agents increasing bleeding potential
• Other acetylcholinesterase inhibitors or cholinergic agents